Iowanews Headlines

Catheter-Related Bloodstream Infections Market

Key companies in this space include Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, and Fresenius Medical Care. Therapies for catheter-related bloodstream infections, such as DEFENCATH and MINO-LOK, are anticipated to drive market growth over the coming years.

DelveInsight has released a comprehensive report titled “Catheter-Related Bloodstream Infections – Market Insights, Epidemiology, and Forecast to 2034”, providing detailed insights into the disease, historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Catheter-related bloodstream infections market report

Some of the key facts of the Catheter-related bloodstream infections Market Report:

• As of May 2025, the FDA approved DefenCath (taurolidine and heparin), marking the first antimicrobial catheter lock solution in the U.S. to reduce catheter-related bloodstream infections (CRBSIs) in adults with kidney failure undergoing chronic hemodialysis via a central venous catheter.

• Citius Pharmaceuticals acquired global rights to MINO-LOK from the University of Texas MD Anderson Cancer Center. MINO-LOK has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation (FTD), with patent protection until 2024 and formulation patents extending to 2036.

• In November 2023, CorMedix’s DEFENCATH gained FDA approval to treat CRBSIs in adult kidney failure patients on chronic hemodialysis. Approval in Europe and Japan could further expand its market reach.

• In May 2024, Citius Pharmaceuticals reported positive topline results from its pivotal Phase III trial of MINO-LOK, which met its primary endpoint by significantly improving time to failure events compared to a clinician-directed anti-infective lock solution.

• The full incidence, progression, and clinical burden of CRBSIs remain poorly understood, and the treatment pipeline is limited, with Citius Pharmaceuticals being the only developer with an active therapy. Rising CRBSI cases and the introduction of new treatments are expected to drive market growth in the coming years.

• Leading companies—including Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, and Fresenius Medical Care—are actively exploring new therapies to enhance the CRBSI treatment landscape. Promising therapies include DEFENCATH, MINO-LOK, and others.

Catheter-related bloodstream infections Overview

Catheter-Related Bloodstream Infection (CRBSI), also known as catheter-related sepsis, occurs when bacteria enter the bloodstream via an intravenous catheter. It is among the most common, severe, and costly complications of central venous catheterization and is the leading cause of hospital-acquired bacteremia. CRBSIs can be caused by a variety of organisms, including coagulase-negative staphylococci, Staphylococcus aureus, enteric gram-negative bacilli, enterococci, streptococci, Pseudomonas, and others.

CRBSI is often suspected in patients with a central venous catheter who develop fever, chills, or unexplained hypotension without other apparent causes. Mild symptoms may include malaise and nausea, while severe cases can present with high fever accompanied by rigors, hypotension, vomiting, or altered mental status, even when the catheter exit site and tunnel appear normal on examination.

The catheter-related bloodstream infection report offers a comprehensive overview of CRBSI, covering its pathophysiology, diagnostic approaches, and a detailed treatment algorithm. It also includes a real-world patient case illustrating the journey from initial symptoms to diagnosis and through the full course of treatment.

Catheter-related bloodstream infections Market Outlook

When a catheter-related bloodstream infection (CRBSI) is suspected, clinical guidelines generally recommend removing the catheter first. If fever persists, antibiotic and antifungal therapies are typically initiated, often starting empirically. Commonly prescribed off-label antibiotics for CRBSI include daptomycin, vancomycin, cefazolin, ampicillin, ciprofloxacin, amikacin, and teicoplanin, while antifungals such as fluconazole and amphotericin B are also used off-label.

The treatment landscape for CRBSI is gradually evolving, with only a single pharmaceutical company currently advancing a novel therapy into late-stage development. Key players, including Citius Pharmaceuticals, are actively evaluating their lead candidates at various clinical stages to explore potential new treatments for CRBSI.

Discover how the Catheter-related bloodstream infections market is rising in the coming years

Catheter Related Bloodstream Infection Marketed Drugs

• DEFENCATH: CorMedix

Catheter-related bloodstream infections Emerging Drugs

• MINO-LOK: Citius Pharmaceuticals

Scope of the Catheter-related bloodstream infections Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Catheter-related bloodstream infections Companies: Citius Pharmaceuticals, CorMedix, Geistlich Pharma, TauroPharm GmbH, Fresenius Medical Care, and others

• Key Catheter-related bloodstream infections Therapies: DEFENCATH, MINO-LOK, and others

• Catheter-related bloodstream infections Therapeutic Assessment: Catheter-related bloodstream infections current marketed and Catheter-related bloodstream infections emerging therapies

• Catheter-related bloodstream infections Market Dynamics: Catheter-related bloodstream infections market drivers and Catheter-related bloodstream infections market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Catheter-related bloodstream infections Unmet Needs, KOL’s views, Analyst’s views, Catheter-related bloodstream infections Market Access and Reimbursement

To know what’s more in our Catheter-related bloodstream infections report, visit https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Catheter-related bloodstream infections Market Report:

1. Catheter-related bloodstream infections market report covers a descriptive overview and comprehensive insight of the Catheter-related bloodstream infections Epidemiology and Catheter-related bloodstream infections market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

2. The Catheter-related bloodstream infections market report provides insights into the current and emerging therapies.

3. The Catheter-related bloodstream infections market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Catheter-related bloodstream infections market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Catheter-related bloodstream infections market.

Got queries? Click here to know more about the Catheter-related bloodstream infections market Landscape

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Catheter-related bloodstream infections Patient Share (%) Overview at a Glance

5. Catheter-related bloodstream infections Market Overview at a Glance

6. Catheter-related bloodstream infections Disease Background and Overview

7. Catheter-related bloodstream infections Epidemiology and Patient Population

8. Country-Specific Patient Population of Catheter-related bloodstream infections

9. Catheter-related bloodstream infections Current Treatment and Medical Practices

10. Unmet Needs

11. Catheter-related bloodstream infections Emerging Therapies

12. Catheter-related bloodstream infections Market Outlook

13. Country-Wise Catheter-related bloodstream infections Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Catheter-related bloodstream infections Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Catheter-related bloodstream infections Market Outlook 2034

Related Reports:

Catheter-related bloodstream infections Pipeline Insights, DelveInsight

“Catheter-related bloodstream infections Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Catheter-related bloodstream infections market. A detailed picture of the Catheter-related bloodstream infections pipeline landscape is provided, which includes the disease overview and Catheter-related bloodstream infections treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/